%0 Journal Article
%T Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
%A Byung Woo Jhun
%A Chang-Ki Kim
%A Deog Kyeom Kim
%A Doosoo Jeon
%A Heejung Ahn
%A Ho Jeong Won
%A Jae Ho Lee
%A Jae Seuk Park
%A Jae-Joon Yim
%A Jeongha Mok
%A Ji Yeon Jang
%A Ji Yeon Lee
%A Joong Hyun Ahn
%A Ju Sang Kim
%A Kyung-Wook Jo
%A Myungsun Lee
%A Sang Nae Cho
%A Seokyung Hahn
%A Seung Heon Lee
%A Song Yee Kim
%A Soyoun Shin
%A Sung Jae Shin
%A Tae Sun Shim
%A Taehoon Lee
%A Taeksun Song
%A Won-Jung Koh
%A Young Ae Kang
%A Young Ran Kim
%J Archive of "Trials".
%D 2019
%R 10.1186/s13063-018-3053-1
%X The online version of this article (10.1186/s13063-018-3053-1) contains supplementary material, which is available to authorized users
%K Tuberculosis
%K Multidrug-resistant tuberculosis
%K Multicenter randomized trial
%K Non-inferiority
%K Shorter regimen
%K Delamanid
%K Linezolid
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335682/